ESMO-BC 2022: Interim analysis (n=150) of the multi-national, prospective, non-interventional ELEANOR study observing real-life extended adjuvant treatment with neratinib in patients with HER2+ / HR+ early breast cancer (eBC)
Pierre Fabre snags option on Piqur program in skin cancers | Fierce Biotech
Jairo Pardey - Chief Executive Officer, Hong Kong & Macau - Pierre Fabre Group | LinkedIn
Pierre Fabre and its partner Array BioPharma announce interim analysis results from the BEACON CRC Trial of encorafenib + binimetinib + cetuximab for the treatment of BRAFV600E-mutant metastatic colorectal cancer | Business Wire
Agenda - 100% Radio
Courtney Haas - Pharmaceutical Representative - Pierre Fabre Group | LinkedIn
Christophe DURAND, new CEO at Cenexi - Cenexi
Coline Rochette - Animatrice de ligne (intérim) - Laboratoires Pierre Fabre | LinkedIn
Togo faure gnassingbe hi-res stock photography and images - Page 3 - Alamy
NICE clears Pierre Fabre's targeted melanoma combo to take on Novartis, Roche drugs | Fierce Pharma
Khaled Laouiti :«Pierre Fabre Tunisie, une plateforme d'export vers l'Afrique sub-saharienne.» - Entreprises Magazine
LABORATORY CORPORATION OF AMERICA HOLDINGS 2022 NPS
Pierre Fabre Dermo-Cosmetics - Xavier Ormancey appointed R&D Director
Pierre Fabre and its partner Array BioPharma announce interim analysis results from the BEACON CRC Trial of encorafenib + binimetinib + cetuximab for the treatment of BRAFV600E-mutant metastatic colorectal cancer | Business Wire
Pierre Fabre and its partner Array BioPharma announce interim analysis results from the BEACON CRC Trial of encorafenib + binimetinib + cetuximab for the treatment of BRAFV600E-mutant metastatic colorectal cancer | Business Wire
In Guinea and Togo, Autocratic Leaders Are Rolling Back Democracy to Cling to Power
Les Laboratoires Pierre Fabre dévoilent leur nouvelle gouvernance
Pierre Fabre : une nouvelle gouvernance expérimentée | Les Echos
Le groupe Pierre Fabre dans l'expectative après le décès de son fondateur | Les Echos
